Report on the Drug Situation 2010 - Bundesministerium fÃ¼r ...

More documents

Recommendations

Info

greatest percentage of the respective sums has in turn been provided by the provinces(ÖBIG 2002). More recent figures on provincial expenditure in this specific field are notavailable. In addition, treatment centres announced in the Federal Collection ofStatutes according to Section 15 of the SMG may receive funding from the FederalMinistry of Health. In 2009 this amounted to a total of EUR 2 051 868 (communicationby the Federal Ministry of Health). Part of this sum is also spent for inpatient drugtreatment.Table 12.2Outpatients, estimated number of days of service delivery and funding sources, intreatment centres covered by DOKLI, in 2009CoveragePeopletreated 1Health insurancefundSource of funding (percentages) 2ProvincesCourtauthoritiesNo per-casefundingAustria, nationwide 9 759 - - - -Austria excl. Vienna 6 556 10% 26% 3% 63%Note 1: All people treated in 2009.Note 2: Percentage of actual funding source, investigated at the end of treatment, relating to those patientswhose outpatient treatment ended in 2009, not including Vienna (multiple answers were permitted). The figuresrelating to funding source do not include Vienna because data on funding sources are not transferred fromVienna's BADO documentation system to the nationwide DOKLI system (see GÖG/ÖBIG 2010a).Source: GÖG/ÖBIG, DOKLI analysis of client year 2009; representation by GÖG/ÖBIGNo data on costs per day of outpatient treatment are available.12.4 Cost of substitution treatmentAlthough there are problems regarding the data quality of the substitution registry(e.g., ghost cases; see Chapters 4.1 and 5.4 as well as GÖG/ÖBIG 2010b), it is stillobvious that the number of people undergoing opioid substitution treatment hasstrongly risen over the years (see Chapter 5.4). For 2009, the number of 'OST-days' 50is estimated to be between 2.4 and 4 million.50The total of 10 837 people in substitution treatment on 30 June 2009 multiplied by 365. In order to take intoaccount ghost cases, the lower limit of 60% of the number derived has been given (see GÖG/ÖBIG 2010b).112 © GÖG/ÖBIG, <strong>Report</strong> on the Drug Situation 2010
According to the Main Association of Austrian Social Security Institutions, the cost ofsubstitution medicines taken over by the social security institutions was EUR 25 millionin 2009. Only substances that are exclusively prescribed for substitution treatmenthave been considered here (Näglein, personal communication).Because in most provinces OST is primarily provided by established doctors, visits tothese physicians are relevant for costs. Only Vienna, Upper Austria and the Tyrol granta separate OST remuneration in addition to the standard fees for consultations withdoctors: in Vienna, EUR 26 per patient may be charged ten times a quarter at the most;in Upper Austria, it is EUR 65 for first-time and renewed stabilisation and EUR 20 fivetimes a quarter for subsequent treatment; and doctors in the Tyrol may charge EUR 25three times a quarter (Schwarzenbrunner, personal communication). In Salzburg, where90% of substitution treatments are delivered by the SUST Substitution Centre for OpiateAddicts and the Drug Outpatient Department of Christian Doppler Hospital, the healthinsurance funds grant a lump sum of EUR 202 per quarter plus reimbursement ofexpenses of EUR 74 for substitution substances per patient and month, in the case ofpatients who have health insurance. If patients do not carry insurance, the correspondingcosts are taken over by the Province (Schabus-Eder, personal communication).In Carinthia the social insurance institutions pay EUR 62 a year for diagnosing, firsttreatment and renewed stabilisation, plus EUR 19 five times a quarter at the most.Here, almost all substitution treatments are carried out by two established outpatientclinics not affiliated to hospitals. In Vorarlberg, established doctors who haveadditional consulting hours in drug treatment centres may obtain EUR 74 per quarterand patient (Schwarzenbrunner, personal communication; see also Chapter 5.1).Regarding cost of substitution medicines for prisoners, figures for 2009 are available:approximately EUR 1.4 million was spent for substitution substances. The average costper patient amounted to EUR 1 470 (Parliament enquiry No. 4288/J-NR/2010).12.5 ConclusionsBecause of the complex financing structure and budgets which are not broken down bydrug-related spending in most cases, expenditure for drug-related treatment can onlybe given as a rough estimate. A detailed analysis of the corresponding cost wouldrequire much time and involve considerable cost, and no studies on this subject areavailable. The selected issues chapter of our 2002 <strong>Report</strong> to the EMCDDA (ÖBIG 2002)provides some information in this field: the overall cost of drug-related treatment wasestimated to amount to EUR 40 770 400 in 1999 and EUR 50 736 800 in 2001. Thesefigures include expenditure for inpatient and outpatient treatment centres, opioidsubstitution treatment, interventions according to the principle of therapy instead ofpunishment, treatment in prison, inpatient treatment in hospital as well as summarisedother expenses by health insurance funds. As some of the available data indicate aconsiderable rise in treatment cost compared to the years studied for the 2002 reportChapter 12 / Cost of Drug-related Treatment 113
Page 1:
Report on the Drug
Page 4 and 5:
ISBN-13 978-3-85159-153-8Owner, edi
Page 6 and 7:
PreventionThe trend towards drawing
Page 8 and 9:
hardly known. This makes it impossi
Page 10 and 11:
6 Health Correlates and Consequence
Page 12 and 13:
Tables and FiguresTablesTable 6.1Ta
Page 14 and 15:
Table A22Table A23Table A24Table A2
Page 16 and 17:
Figure 9.1Figure 9.2Figure 9.3Figur
Page 19:
Part ANew Developmentsand Trends
Page 22 and 23:
The amendment to the Narcotic Drugs
Page 24 and 25:
deaths (see GÖG/ÖBIG 2009b) conti
Page 26 and 27:
In the reporting period, no new dev
Page 28 and 29:
2.1 Drug use in the general populat
Page 30 and 31:
The quitting rate 3 is considerably
Page 32 and 33:
Figure 2.2Experience of cannabis us
Page 34 and 35:
described on the individual website
Page 36 and 37:
ehaviour is elevated for children i
Page 38 and 39:
theme of the Gesunde Gemeinden (hea
Page 40 and 41:
party scenes are relevant settings.
Page 42 and 43:
support if needed. The project is i
Page 44 and 45:
approximations and have to be inter
Page 46 and 47:
Figure 4.22-sample CRC estimates wi
Page 48 and 49:
5 Drug-related Treatment: Treatment
Page 50 and 51:
2010, now 50 doctors are entitled t
Page 52 and 53:
patients for inpatient treatment al
Page 54 and 55:
Map 5.2Specialised providers of out
Page 56 and 57:
cooperation structures linking the
Page 58 and 59:
events are organised, and on the ot
Page 60 and 61:
5.3 Characteristics of treated clie
Page 62 and 63:
play the most important role in the
Page 64 and 65:
existing treatment system who do no
Page 66 and 67:
5.4 Trends of clients in treatmentA
Page 68 and 69:
Figure 5.7First substitution treatm
Page 70 and 71:
6 Health Correlates and Consequence
Page 72 and 73:
Table 6.1Data on hepatitis B, hepat
Page 74 and 75:
ange from affective disorders (e.g.
Page 76 and 77:
Figure 6.1Share of directly drug-re
Page 78 and 79: In the EMCDDA working group on coho
Page 80 and 81: 7 Responses to Health Correlates an
Page 82 and 83: 7.2 Prevention and treatment of dru
Page 84 and 85: distribution of condoms) is provide
Page 86 and 87: information on the risks of additio
Page 88 and 89: While smaller shares of women state
Page 90 and 91: Map 8.1Specialised providers of inp
Page 92 and 93: The Lighthouse housing project of M
Page 94 and 95: empowerment that had been aimed at,
Page 96 and 97: handling of drugs: Section 27 of th
Page 98 and 99: also shows regarding prison sentenc
Page 100 and 101: Stadtpark, and Westbahnhof station.
Page 102 and 103: mation on final convictions because
Page 104 and 105: practitioners and psychiatrists). I
Page 106 and 107: 10 Drug MarketsThe substance most f
Page 108 and 109: head shop in Graz (Styria) in Augus
Page 110 and 111: (from 2005 to 2008, the correspondi
Page 113: Part BSelected Issues
Page 116 and 117: national quality standards for medi
Page 118 and 119: Also, both at federal and provincia
Page 120 and 121: Table 11.1, continuedTitle and year
Page 122 and 123: Plans for new guidelines and standa
Page 124 and 125: 12 Cost of Drug-related TreatmentTh
Page 126 and 127: centres so far (Schweizer Haus Hade
Page 130 and 131: (e.g., days of hospital stay becaus
Page 133 and 134: BibliographyAPA 2010. AIDS 2010. Wi
Page 135 and 136: EMCDDA 2000. Treatment demand indic
Page 137 and 138: Haas, S. (2005). Problembewusste Fr
Page 139 and 140: Pont, J.; Wool, R. (2006). Ein Leit
Page 141 and 142: VIVID 2010. Jahresbericht 2009. VIV
Page 143 and 144: Personal Communications(alphabetica
Page 145 and 146: Caritas Marienambulanz. Drug relate
Page 147 and 148: Low threshold service Ganslwirt(Ver
Page 149 and 150: Viennese pilot project “Pregnancy
Page 151 and 152: Lower Austria: Fachstelle für Such
Page 153 and 154: Caritas Innsbruckhttp://www.caritas
Page 155 and 156: Otto-Wagner-Spital — Drogeninstit
Page 157: AnnexA. Tables, MapB. List of Abbre
Page 161 and 162: Table A1Overview of selected genera
Page 163 and 164: Table A2, continuedStudy(author(s),
Page 165 and 166: Table A5Number of directly drug-rel
Page 167 and 168: Table A7Distribution of directly dr
Page 169 and 170: Table A11Distribution of reports of
Page 171 and 172: Table A15Final convictions under th
Page 173 and 174: Table A18Seizures of narcotic drugs
Page 175 and 176: Table A22Persons starting drug trea
Page 177 and 178: Table A24Persons starting drug trea
Page 179 and 180:
Table A26Persons starting drug trea
Page 181 and 182:
Table A29Current health problems of
Page 183 and 184:
The programme plus is implemented i
Page 185 and 186:
Proven regional interventions run f
Page 187 and 188:
Table A34Austrian population statis
Page 189:
Annex BList of Abbreviations
Page 192 and 193:
HCVHCV-AbHCV-RNAHIVICD-10IFESISDISP
Page 195 and 196:
List of Standard Tables of 2010 and
Page 197:
© Gesundheit Österreich GmbHStube
show all

Report on the Drug Situation 2010 - Bundesministerium fÃ¼r ...

Create successful ePaper yourself

Delete template?

Save as template?